Related references
Note: Only part of the references are listed.Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model
Anna Johansson et al.
BJU INTERNATIONAL (2011)
ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading
Paul Mak et al.
CANCER CELL (2010)
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hiroya Hashizume et al.
CANCER RESEARCH (2010)
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
W. K. Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
Iris Helfrich et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2010)
ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer
Helene Gustavsson et al.
BJU INTERNATIONAL (2009)
Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts
K. Welen et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2009)
Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models
Tajana Tesan et al.
BJU INTERNATIONAL (2008)
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer
Karsten Gravdal et al.
CLINICAL CANCER RESEARCH (2007)
Vascular endothelial growth factor and angiopoietin are required for prostate regeneration
Gui-min Wang et al.
PROSTATE (2007)
Angiotensin II type I receptor antagonist as an angiogenic inhibitor in prostate cancer
Takeo Kosaka et al.
PROSTATE (2007)
Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats
A Johansson et al.
ENDOCRINOLOGY (2005)
Angiopoietin 2 expression is related to histological grade,vascular density, metastases, and outcome in prostate cancer
AJ Lind et al.
PROSTATE (2005)
Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis
H Gustavsson et al.
PROSTATE (2005)
Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer
G Aslan et al.
PATHOLOGY RESEARCH AND PRACTICE (2005)
Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
WS Moon et al.
MODERN PATHOLOGY (2003)
Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo
IB Lobov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer
AF West et al.
BRITISH JOURNAL OF CANCER (2001)
Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer
S Häggström et al.
BJU INTERNATIONAL (2001)
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
RJ Stewart et al.
JOURNAL OF UROLOGY (2001)
Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
A Jones et al.
BJU INTERNATIONAL (2000)
Share Paper
